The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics

Jiaqiong Wang; Aldo Serafini; Russ Kuker; Cyrus Ayubcha; Gary Cohen; Helen Nadel; Alexander McKinney; Abass Alavi; Jian Q Yu

doi:10.1016/j.cpet.2024.09.009

The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics

Jiaqiong Wang, Aldo Serafini, Russ Kuker, Cyrus Ayubcha, Gary Cohen, Helen Nadel, Alexander McKinney, Abass Alavi, Jian Q Yu

Research output: Contribution to journal › Review article › peer-review

Abstract

MR imaging is currently the main imaging modality used for the diagnosis and post therapeutic assessment of glioblastomas. Recently, several innovative PET radioactive tracers have been investigated for the evaluation of glioblastomas (GBM). These radiotracers target several biochemical and pathophysiological processes seen in tumors. These include glucose metabolism, DNA synthesis and cell proliferation, amino acid transport, cell membrane biosynthesis, specific membrane antigens such as prostatic specific membrane antigens, fibroblast activation protein inhibitor, translocator protein and hypoxia sensing agents, and antibodies targeting specific cell receptor antigen. This review aims to discuss the clinical value of these PET radiopharmaceuticals in the evaluation and treatment of GBMs.

Original language	English
Pages (from-to)	147-164
Number of pages	18
Journal	PET Clinics
Volume	20
Issue number	1
DOIs	https://doi.org/10.1016/j.cpet.2024.09.009
State	Accepted/In press - Oct 30 2024

Keywords

Fibroblast activation protein inhibitor (FAPI)
Glioblastoma
PET
Prostatic-specific membrane antigens (PSMA)
Theranostics

Access to Document

10.1016/j.cpet.2024.09.009

Cite this

@article{bc81ffe3281f4832817c3234be97b420,

title = "The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics",

abstract = "MR imaging is currently the main imaging modality used for the diagnosis and post therapeutic assessment of glioblastomas. Recently, several innovative PET radioactive tracers have been investigated for the evaluation of glioblastomas (GBM). These radiotracers target several biochemical and pathophysiological processes seen in tumors. These include glucose metabolism, DNA synthesis and cell proliferation, amino acid transport, cell membrane biosynthesis, specific membrane antigens such as prostatic specific membrane antigens, fibroblast activation protein inhibitor, translocator protein and hypoxia sensing agents, and antibodies targeting specific cell receptor antigen. This review aims to discuss the clinical value of these PET radiopharmaceuticals in the evaluation and treatment of GBMs.",

keywords = "Fibroblast activation protein inhibitor (FAPI), Glioblastoma, PET, Prostatic-specific membrane antigens (PSMA), Theranostics",

author = "Jiaqiong Wang and Aldo Serafini and Russ Kuker and Cyrus Ayubcha and Gary Cohen and Helen Nadel and Alexander McKinney and Abass Alavi and Yu, {Jian Q}",

year = "2024",

month = oct,

day = "30",

doi = "10.1016/j.cpet.2024.09.009",

language = "English",

volume = "20",

pages = "147--164",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics

AU - Wang, Jiaqiong

AU - Serafini, Aldo

AU - Kuker, Russ

AU - Ayubcha, Cyrus

AU - Cohen, Gary

AU - Nadel, Helen

AU - McKinney, Alexander

AU - Alavi, Abass

AU - Yu, Jian Q

PY - 2024/10/30

Y1 - 2024/10/30

N2 - MR imaging is currently the main imaging modality used for the diagnosis and post therapeutic assessment of glioblastomas. Recently, several innovative PET radioactive tracers have been investigated for the evaluation of glioblastomas (GBM). These radiotracers target several biochemical and pathophysiological processes seen in tumors. These include glucose metabolism, DNA synthesis and cell proliferation, amino acid transport, cell membrane biosynthesis, specific membrane antigens such as prostatic specific membrane antigens, fibroblast activation protein inhibitor, translocator protein and hypoxia sensing agents, and antibodies targeting specific cell receptor antigen. This review aims to discuss the clinical value of these PET radiopharmaceuticals in the evaluation and treatment of GBMs.

AB - MR imaging is currently the main imaging modality used for the diagnosis and post therapeutic assessment of glioblastomas. Recently, several innovative PET radioactive tracers have been investigated for the evaluation of glioblastomas (GBM). These radiotracers target several biochemical and pathophysiological processes seen in tumors. These include glucose metabolism, DNA synthesis and cell proliferation, amino acid transport, cell membrane biosynthesis, specific membrane antigens such as prostatic specific membrane antigens, fibroblast activation protein inhibitor, translocator protein and hypoxia sensing agents, and antibodies targeting specific cell receptor antigen. This review aims to discuss the clinical value of these PET radiopharmaceuticals in the evaluation and treatment of GBMs.

KW - Fibroblast activation protein inhibitor (FAPI)

KW - Glioblastoma

KW - PET

KW - Prostatic-specific membrane antigens (PSMA)

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=85207753875&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2024.09.009

DO - 10.1016/j.cpet.2024.09.009

M3 - Review article

C2 - 39482219

SN - 1556-8598

VL - 20

SP - 147

EP - 164

JO - PET Clinics

JF - PET Clinics

IS - 1

ER -

The State-of-the-Art PET Tracers in Glioblastoma and High-grade Gliomas and Implications for Theranostics

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this